ORPH.L Regulatory News (ORPH)

Venn Life Sciences Holdings Plc

("Venn" the "Company" or the "Group")

Trading update

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces a strong first half of 2015 with the Company billing in excess of €4m, up 170% against the same period in 2014 (H1: €1.5m).

The Company has demonstrated continued growth throughout 2015 driven by contract wins amounting to over €9m in the period to 30 June 2015.

Commenting on the figures, Venn CEO, Tony Richardson said: "Our fee income figures highlight the steady and consistent growth of the Company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally. Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth."

Venn will announce its interim results for the six months ended 30 June 2015 on the 22 September 2015.

For further information:

Enquiries:

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.